[
    "genet polymorph drugmetabolis enzym nqo sulta ephx nat alter activ hamper detoxif dispos chemotherapeut compound thu present studi comprehens investig associ snp phase ii detoxifi gene relationship toward platinuminduc toxic lung cancer patientsnqo c sulta arg ephx tyrhi hisarg nat c g g g evalu studi associ advers event caus due administr platinumbas chemotherapi lung cancer patientsfor nqo c polymorph tt genotyp show reduc risk constip p anorexia p sulta arghi heterozyg genotyp arghi aor p combin genotyp arghi hishi associ increas risk nephrotox aor p nat heterozyg nat combin genotyp nat nat polymorph exhibit fold p twofold p increas risk hematolog toxic heterozyg aor p variant genotyp aor p natc decreas risk hematolog toxic heterozyg genotyp nat polymorph show twofold increas risk develop thrombocytopeniathi studi provid associ nat polymorph variant predict haematolog toxic",
    "purpos compar safeti v offclamp robot partial nephrectomi rapn method patient renal mass random undergo onclamp v offclamp rapn clock trialclinicaltrialsgov nct seven institut one experienc surgeon per institut intraop data complic posit surgic margin compar result due relev rate shift assign treatment perprotocol analysi consid data onclamp v offclamp rapn analyz tumor size offclamp v onclamp v cm p gdl v p transfus rate v p reintervent due bleed v p acut kidney injuri v p posit surgic margin v p multivari analysi account tumor diamet complex consid onclamp group refer categori signific differ note offclamp group exclus blood loss ci p conclus onclamp offclamp approach rapn show compar safeti profil",
    "background pauciti literatur regard associ high oncot prime solut pediatr cardiopulmonari bypass cpb outcom consensu exist regard composit optim cpb prime solut studi aim examin impact high oncot pressur prime addit human albumin outcom method doubleblind random control studi done pediatr cardiac intens care unit tertiari care hospit consecut child congenit heart diseas admit openheart surgeri random two group studi group receiv addit albumin convent blood prime cpb initi result enrol child high oncot prime ad albumin group child convent prime group first hour postop period child albumin group significantli lower occurr hypotens v p requir fluid bolu v p lactat clearanc time v hour p albumin group also significantli higher platelet count l hour v p signific differ intracpb hemodynam paramet incid acut kidney injuri subgroup analysi base risk categori significantli decreas intens care unit stay v day p hospit stay v day p found albumin group lowrisk categori conclus high oncot pressur cpb prime use albumin addit might benefici convent blood prime studi provid rational studi",
    "object aim studi examin possibl influenc minor deterior renal function stent implant fulfil criterion acut kidney injuri longterm outcom stent thrombosi st background decreas renal function drf associ increas risk wors outcom percutan coronari intervent data deterior renal function stent implant influenc prognosi st patient higher risk wors outcom st could identifi alreadi time stent implant method data consecut patient treat percutan coronari intervent center record march april exclud patient acut kidney injuri stent implant st without acut kidney injuri stent implant involv studi prospect follow decemb month patient definit st includ studi academ research consortium definit st use data death myocardi infarct repeat percutan oper revascular st ascertain hospit databas phone clinic examin outcom definit st compar patient without deterior renal function stent implant drfaftersi result observ period patient drfaftersi higher mortal rate st patient without drfaftersi v p year adjust hr ci p could find predictor mace conclus even subtl drfaftersi fulfil criterion acut kidney injuri stent implant associ higher longterm mortal st especi risk patient older year stent implant drfaftersi age year point group patient high risk death st alreadi time stent implant best treatment option prevent st patient still determin must pay special attent proper patient prepar hydrat avoid drfaftersi",
    "object compar patient underw retrograd intraren surgeri without ureter access sheath ua use kidney injuri molecul kim level also examin differ kidney damag standard dual lumen ua sixti patient diagnos kidney stone schedul rir random three group rir without ua group frfr boston scientif navig ua group frfr dual lumen clearpetra ua group data prospect collect consecut patient urin kimcr level measur preoper postop h postop day stone size locat number pre postop stent use oper time stonefre rate sfr postureteroscop lesion scale pul grade hospit durat complic record signific differ demograph paramet preoper kimcr level among group postop thhour urin kimcr level higher patient without ua patient ua group respect compar group group separ group statist significantli higher valu group p p respect accord ua type signific differ group use ua rir shown reduc kidney injuri evalu kim differ ua type kidney injuri one protect kidney procedur elucid prospect random studi involv larger patient group ua type",
    "purpos evalu feasibl potenti efficaci nanocurcumin supplement patient local muscleinvas bladder cancer mibc undergo induct chemotherapi materi method doubleblind placebocontrol trial mibc patient random receiv either nanocurcumin mgday placebo cours chemotherapi patient follow four week end treatment assess complet clinic respons chemotherapi primari endpoint secondari endpoint comparison chemotherapyinduc nephrotox hematolog nadir toxic two group hematolog nadir toxic assess treatment result nanocurcumin well toler complet clinic respons rate placebo nanocurcumin group respect although nanocurcumin shown superior placebo respect complet clinic respons rate primari endpoint signific differ group p signific differ also found two group regard grade renal hematolog toxic well hematolog nadir conclus preliminari data indic feasibl nanocurcumin supplement complementari therapi mibc patient support larger studi moreov substanti translat insight fill gap experi clinic practic field provid",
    "introduct european bone sarcoma studi euroboss first prospect intern studi patient year old highgrad bone sarcoma treat intens chemotherapi regimen deriv protocol younger patient highgrad skelet osteosarcoma method chemotherapi base doxorubicin cisplatin ifosfamid methotrex suggest patient treat regimen investig choic also elig studi result present report focu subgroup patient primari highgrad osteosarcoma median followup month year probabl overal surviv o patient local diseas case synchron metastasi year o patient local diseas pelvic tumor extrem craniofaci locat respect primari chemotherapi tumor necrosi report patient toxic death howev hematolog toxic consider patient experienc episod neutropen fever incid nephrotox neurotox mainli peripher respect methotrex patient experienc delay excret case nephrotox conclus patient year age primari highgrad osteosarcoma aggress approach chemotherapi surgeri offer probabl surviv similar achiev younger patient chemotherapyrel toxic signific gener higher report younger cohort osteosarcoma patient treat intens regimen",
    "background explor feasibl effect segment sodium citrat solut anticoagul strategi patient receiv crrt method prospect random control studi conduct result accord inclus exclus criterion patient includ randomli divid two group moreov coagul index liver function index renal function index sofa apach ii score significantli differ two group p coagul grade venou port experiment group lower control group two group filter differ statist signific p sodium citrat solut infus method maintain low blood calcium concentr mmoll peripher circul pathway patient develop hypocalcaemia mmoll lifespan extracorpor circul tube experiment group control group h h respect p conclus segment citrat solut anticoagul strategi could extend lifespan extracorpor circul tube improv crrt efficaci trial registr chines clinic trial registri number chictr regist march",
    "background vancomycin commonli prescrib antibiot treat gramposit infect efficaci vancomycin known directli relat pharmacokineticpharmacodynam pkpd index area concentrationtim curv auc divid minim inhibitori concentr mic pathogen howev countri steadyst plasma concentr use surrog paramet target aucmic practic drawback henc direct aucguid monitor vancomycin use modelinform precis dose mipd tool propos earlier attain target concentr reduc vancomycinrel nephrotox howev solid scientif evid benefit clinic practic still lack random control trial rct aim investig clinic util mipd dose vancomycin administ via continu infus hospit adult method particip ward two belgian hospit randomli alloc intervent group standardofcar compar group intervent group clinic pharmacist perform dose calcul use celabel mipd softwar target auch mg hl wherea patient compar group receiv standardofcar dose monitor accord institut guidelin primari endpoint proport patient reach target auchmic h start vancomycin treatment secondari endpoint proport patient worsen acut kidney injuri aki h stop vancomycin treatment proport patient reach target auchmic h start vancomycin treatment proport time within target auchmic discuss trial clarifi propag benefit provid new insight optim monitor vancomycin treatment trial registr eudract number regist june clinicaltri gov identifi nct regist septemb protocol version protocol date april",
    "background shiga toxinproduc e coli stec infect affect child adult worldwid treatment remain sole support child infect highrisk stec ie e coli produc shiga toxin develop hemolyt anemia thrombocytopenia kidney failur ie hemolyt urem syndrom hu half requir acut dialysi die although therapi wide accept abl prevent develop hu complic sever observ studi suggest intravascular volum expans hyperhydr may prevent end organ damag random trial need confirm refut hypothesi method conduct pragmat embed clusterrandom crossov trial pediatr institut determin hyperhydr compar conserv fluid manag improv outcom child highrisk stec infect primari outcom major advers kidney event within day make composit measur includ death initi new renal replac therapi persist kidney dysfunct secondari outcom includ lifethreaten extraren complic develop hu pathway elig child treat per institut alloc pathway hyperhydr pathway elig child hospit administ mainten balanc crystalloid fluid target weight gain reduct hematocrit site conserv fluid manag pathway manag child outpati base clinician prefer pathway focus close laboratori monitor mainten euvolemia base histor data estim child conserv fluid manag pathway experi primari outcom cluster enrol mean patient intraclass correl coeffici power detect absolut risk reduct discuss hu devast ill treatment option pragmat studi determin hyperhydr reduc morbid associ hu child highrisk stec infect trial registr clinicaltrialsgov nct regist februari"
]